1. Home
  2. ACAD vs SUNC Comparison

ACAD vs SUNC Comparison

Compare ACAD & SUNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.41

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo SunocoCorp LLC

SUNC

SunocoCorp LLC

N/A

Current Price

$66.40

Market Cap

3.2B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ACAD
SUNC
Founded
1993
2000
Country
United States
United States
Employees
N/A
8910
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.2B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
ACAD
SUNC
Price
$21.41
$66.40
Analyst Decision
Buy
Strong Buy
Analyst Count
22
2
Target Price
$30.55
$61.00
AVG Volume (30 Days)
1.2M
376.9K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
5.74%
EPS Growth
69.12
N/A
EPS
0.02
N/A
Revenue
$726,437,000.00
N/A
Revenue This Year
$18.80
$65.29
Revenue Next Year
$11.70
$0.84
P/E Ratio
$1,092.00
N/A
Revenue Growth
40.45
N/A
52 Week Low
$19.69
$47.00
52 Week High
$28.35
$73.24

Technical Indicators

Market Signals
Indicator
ACAD
SUNC
Relative Strength Index (RSI) 47.59 47.21
Support Level $21.04 $64.70
Resistance Level $22.03 $68.32
Average True Range (ATR) 0.60 1.49
MACD 0.06 -0.54
Stochastic Oscillator 55.62 19.78

Price Performance

Historical Comparison
ACAD
SUNC

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About SUNC SunocoCorp LLC

SunocoCorp LLC is a publicly traded limited liability company that owns a direct limited partner interest in Sunoco LP. It engages in the management and distribution of fuel products. It operates through the following segments: Fuel Distribution, Pipeline Systems, and Terminals and Refinery.

Share on Social Networks: